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We sought to develop a nanoparticle vehicle that could eﬃciently deliver small molecule drugs to target
lymphocyte populations. The synthesized amphiphilic organic ligand-protected gold nanoparticles
(amph-NPs) were capable of sequestering large payloads of small molecule drugs within hydrophobic
pockets of their ligand shells. These particles exhibit membrane-penetrating activity in mammalian cells,
and thus enhanced uptake of a small molecule TGF-β inhibitor in T cells in cell culture. By conjugating
amph-NPs with targeting antibodies or camelid-derived nanobodies, the particles’ cell-penetrating pro-
perties could be temporarily suppressed, allowing targeted uptake in speciﬁc lymphocyte subpopulations.
Degradation of the protein targeting moieties following particle endocytosis allowed the NPs to recover
their cell-penetrating activity in situ to enter the cytoplasm of T cells. In vivo, targeted amph-NPs showed
40-fold enhanced uptake in CD8+ T cells relative to untargeted particles, and delivery of TGF-β inhibitor-
loaded particles to T cells enhanced their cytokine polyfunctionality in a cancer vaccine model. Thus, this
system provides a facile approach to concentrate small molecule compounds in target lymphocyte popu-
lations of interest for immunotherapy in cancer and other diseases.
Introduction
Immunotherapies are now an established component of the
armamentarium for treating metastatic cancer, with a rapidly
growing list of approved drugs and disease indications.
Important examples include the checkpoint blockade thera-
peutics such as antibodies against the negative regulatory
receptors PD-1 or CTLA-4 1,2 and chimeric antigen receptor T
cell therapy for leukemia.3,4 However, strategies to increase the
proportion of patients gaining a benefit from these treatments
and/or increasing the durability of immune-mediated tumor
regressions are still urgently needed.
Much eﬀort to date has focused on targeting cell surface
receptors on T cells (and other lymphocytes) with agonistic or
blocking antibodies – e.g., checkpoint blockade.5 A comp-
lementary approach would be modulation of intracellular sig-
naling pathways directly via small molecule drugs, which
might augment T cell function via inhibition of suppressive
signaling pathways or by activation of stimulatory signaling
nodes. A limitation of such small molecule-based immuno-
modulation is the likelihood of generalized toxicity as these
compounds distribute widely to both tumor antigen-specific
and irrelevant lymphocytes throughout the body; such toxicities
may be amplified if the signaling pathway of interest in T cells
is common to other cell types. Signaling from Transforming
Growth Factor-β (TGF-β) provides an example of this challenge:
TGF-β is a multifunctional cytokine that regulates cell diﬀeren-
tiation and proliferation.6 In the context of tumor immunity,
TGF-β is an immunosuppressive cytokine that is often over-
expressed in the tumor microenvironment,7,8 and TGF-β sig-
naling inhibits T cell proliferation and eﬀector function.9–15
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TGF-β-deficient animals spontaneously reject some tumors,16
and therapeutic inhibition of this pathway has shown eﬃcacy
in mouse models of cancer.17–21 However, almost every cell in
the body produces TGF-β and has specific receptors for it. The
essential role of TGF-β for survival has been illustrated in TGF-
β1 knockout mice, 50% of which die in utero, with survivors
suﬀering severe inflammation-related conditions after
birth.22,23 Thus, systemic administration of TGF-βi is associ-
ated with adverse eﬀects.6,24–26 We previously sought to target
a small molecule inhibitor of TGF-β specifically to CD8+ T cells
via antibody-targeted liposomes.15 Although these nano-
carriers were eﬀective in reversing TGF-β signaling in lympho-
cytes in vitro, their impact on T cell function in vivo was
modest, likely in part due to low drug loading characteristic of
these traditional drug delivery vehicles.
Here, we describe a novel lymphocyte-targeted small mole-
cule drug delivery platform, based on very small cell mem-
brane-penetrating amphiphilic gold nanoparticles (amph-
NPs). These particles have a 2–3 nm diameter gold core sur-
rounded by an amphiphilic organic ligand shell, a mixed
monolayer of alkanethiols terminated by hydrophobic methyl
and water-solubilizing sulfonate groups.27 Flexibility of the
organic ligands allows these particles to embed within lipid
bilayers and transit across bilayers to enter cells in a non-toxic
manner.28–31 As described below, we discovered that these par-
ticles could also sequester substantial quantities of small
molecule drug within the hydrophobic pockets of the ligand
shell. This finding led us to hypothesize that conjugation of
such drug-loaded particles with whole antibodies or antibody
fragments could be used to both (i) temporarily restrict their
membrane-penetrating activity and (ii) direct their uptake into
specific target cell types. Following binding of the antibody to
a target receptor and receptor-mediated endocytosis, proteol-
ysis of the targeting moiety within the endolysosomal pathway
would unmask the membrane-penetrating behavior of the par-
ticles, allowing subsequent dissemination through the cyto-
plasm to avoid exocytosis and concentrate the drug throughout
the cell. To test this hypothesis, we conjugated both whole
antibodies and camelid-derived single-chain antibody frag-
ments to amph-NPs, demonstrated their targeted uptake into
CD8+ T cells in vitro and in vivo, and showed the temporal
traﬃcking of these particles to the cytoplasm in lymphocytes.
Targeted amph-NPs substantially enhanced uptake of a TGF-β
receptor small molecule inhibitor into T cells and promoted
enhanced responses to a cancer vaccine, demonstrating a new
approach to modulate the function of target cell populations
in vivo.
Materials and methods
Nanoparticle synthesis
11-Mercaptoundecane sulfonate ligand (MUS) was synthesized
as previously reported.27 All other chemicals were purchased
from Sigma-Aldrich and used without further purification.
0.9 mmol gold(III) chloride trihydrate (99.9%) was dissolved in
150 mL of ethanol and 0.75 mmol of ligands (MUS and 1-octa-
nethiol (OT)) at a molar ratio of 1 : 1 MUS : OT were added to
the solution. After 15 minutes of stirring at 900 rpm, an etha-
nolic solution of sodium borohydride (NaBH4 – 10 times
molar excess over gold salt in 150 ml ethanol) was added drop-
wise to the solution at 25 °C. Black precipitates were observed
almost immediately. The final suspension was stirred for an
additional 3 hours to ensure reduction of the gold salts. The
reaction was quenched by removing the solvent with centrifu-
gation. To remove unreacted chemicals, additional washes
with acetone and ethanol were carried out. Finally, water-
soluble salts and any residual free ligands were removed using
a centrifugal dialysis membrane (Amicon, MWCO 30 kDa).
Nanoparticle sizes were characterized by TEM and individual
syntheses typically returned mean particle sizes of 2.5–3.5 nm
diameter. PEGylated gold nanoparticles (2.1 ± 0.86 nm) coated
by thiol-terminated poly(ethylene glycol) (molecular weight
282.35 g mol−1) were purchased from NanoPartz™.
BODIPY fluorescent labeling of gold nanoparticles
Fluorescent dye BODIPY 630/650-X NHS Ester (Invitrogen) and
thiol linker (11-mercaptoundecyl amine hydrochloride;
Prochimia, Poland) were used as received. 3 mg BODIPY dye
and 1.5 mg thiol linker were dissolved in argon-purged amine-
free dimethyl formamide and stirred for 6 h in the dark. 3 ml
water was added to the solution and stored at 4 °C as a stock
solution. To label the nanoparticles with thiol-functionalized
Bodipy dye, 10 mg amph-NPs were dissolved in 0.75 ml of
water in which 15 μl BODIPY stock solution was added. The
reaction was left stirring for 48 h in the dark at 25 °C. Finally,
10 ml acetone was added to the reaction and NPs were washed
at least three times to remove unreacted dye via centrifugation
for 5 min at 14 000 rpm in a tabletop centrifuge.
Transmission electron microscopy imaging of nanoparticles
To analyze size distributions of gold nanoparticles, 10 μL of
nanoparticle solution at 2 mg mL−1 was deposited on a carbon
coated copper grid, and allowed for 10 min deposition.
Residual solution was blotted away using a filter paper and the
grid was air-dried. Images were taken under JEOL 2010 FEG
Analytical Electron Microscope at 200 kV.
Drug loading and quantification
TGF-β inhibitor SB525334 (Selleckchem) was dissolved in
ethanol at a concentration of 30 mg mL−1, and mixed with an
aqueous suspension of amph-NPs (10 mg mL−1 in water) at a
molar ratio of 550 drug molecules per NP. The mixture was
placed in a dialysis cassette with 100–500 Da MWCO and
stirred against water (3 L dialysis reservoir) for at least
24 hours. To quantify drug loading eﬃciency, the drug-NP
mixture was retrieved from dialysis cassettes 24 later, and free
unloaded small molecules were removed using 30k amicon
centrifugal tubes at 14kg for 10 minutes. The concentrated sus-
pension of drug-loaded amph-NPs was collected, and a
portion of the batch was used for quantification. To extract
loaded small molecules from the gold core, 0.05 mg of drug-
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loaded NP (∼10 μL) solution was mixed with 5 μL of KCN
(30 mg mL−1) and 85 μL of ethanol for 4 hours on a shaker to
dissolve the gold cores. Clear supernatant was collected and
analyzed by a NanoDrop UV-vis spectrometer at a wavelength
of 370 nm.
Animal care and use
Female C57Bl/6 mice 6–8 weeks of age were purchased from
Jackson Laboratories. Animals were cared for in the AAALAC-
certified MIT animal facility, and all animal procedures were
performed in accordance with the Guidelines for Care and Use
of Laboratory Animals of the NIH and approved by the MIT
Institutional Animal Care and Use Committee following local,
state, and federal guidelines.
Detection of cytosolic TGFβi concentration using HPLC
Primary CD8+ T cells were isolated from spleens of C57Bl/
6 mice using an EasySep™ CD8+ T cell isolation kit (Stemcell
Technologies). T cells were incubated in complete medium
(RPMI containing 10% fetal bovine serum) for 4 h in the pres-
ence of amph-NPs loaded with TGF-βi or free TGF-βi. The con-
centration of drug per cell was then determined by HPLC fol-
lowing cell membrane permeabilization and small molecule
extraction in ethanol. To rupture cell membranes, 106 CD8+ T
cells were sonicated in a water bath for two minutes at 25 °C.
To extract cytosolic TGFβi into the supernatant, 190 μL of
ethanol and 10 μL of β-mercapoethanol were added to the cell
suspension. The mixture was then placed on a shaker over-
night at 25 °C. The resulting cell lysates were centrifuged at
14kg for 10 minutes, and the supernatant containing solubil-
ized TGFbi was loaded into HPLC test vials (80 μL per sample
was injected). Samples were run through a reversed phase C18
column (Gemini® 5 µm C18 110 Å, LC Column 250 × 4.6 mm),
with a 30 min protocol 20%–95% (Acetonitrile + 0.1% TFA;
water + 0.1% TFA). Recovered TGFβi was detected at ∼12.5 min
elution time by UV spectroscopy at 350 nm.
Kinetics of amph-NP uptake in T cells
Splenocytes from C57Bl/6 mice were isolated and T cells in the
cultures were expanded by adding ConA (2 μg mL−1) and IL-7
(1 ng mL−1) in complete RPMI medium for 3 days. Expanded
CD8+ T cells were isolated on day 4 by Easysep negative selec-
tion and 10 million cells were used per condition. Cells were
incubated with 0.1 mg mL−1 of MUSOT amph-NPs at 37 °C for
15 min, 30 min, 4 h, 6 h, and 24 h (triplicate wells per time
point) in complete RPMI media in microtiter plates coated
with anti-CD3 antibodies and soluble anti-CD28. Free NPs
were removed by centrifugation of recovered cells 3 times in
PBS, and cell pellets were lysed by the addition of 200 μL aqua
regia. Samples were dissolved in aqua regia for two days at
25 °C. Five standards composed of known concentration of
MUS/OT amph-NPs were also dissolved in aqua regia in paral-
lel. Prior to analysis, samples were diluted in 2% nitric acid to
a total of 4 mL per tube, and then analyzed by inductively
coupled plasma-optical emission spectroscopy (ICP-OES,
Horiba Activa) to detect total gold content of the samples.
Confocal microscopy and flow cytometry
Naïve CD8+ T cells were isolated from the spleens of C57Bl/6
female mice by Easysep negative selection and labeled with
carboxyfluorescein succinimide ester (CFSE). Cells were incu-
bated with BODIPY-labeled MUSOT amph-NPs for 3 h at 37 °C.
Free NPs were removed by centrifugation and cells were
imaged by confocal microscopy (Zeiss LSM 510) using a 63× oil
lens. Another portion of cells was analyzed by flow cytometry
on a BD FACS Canto.
Anti-CD8 VHH nanobody production
The anti-CD8 VHH nanobody (VHH-X118) has been
described.32 A Cys-terminated version was designed by remov-
ing the C-terminal sortase LPXTG motif from the original con-
struct and introducing a C-terminal cysteine after the polyhisti-
dine tag. The open reading frame was synthesized as a
genomic block (Integrated DNA Technologies) and cloned into
the pHEN6 bacterial expression vector.33 The resulting
plasmid was chemically transformed into WK6 E. coli cells.
Following expression, periplasmic extracts were obtained
through osmotic shock as previously described,34 and his-
tagged VHH protein was purified by aﬃnity chromatography
using Ni-NTA agarose beads (ThermoFisher).
Antibody or nanobody conjugation
Amph-NPs were mixed with a 120-fold molar excess of
11-Amino-1-undecanethiol hydrochloride (Sigma) at a final NP
concentration of 10 mg mL−1 NPs in water and placed on a
shaker for 1 hour at 25 °C for ligand exchange. NPs were
washed in water two times to remove excess unbound ligands
by centrifugation at 14 Kg for 10 minutes using Amicon
30 kDa MWCO filters. A third wash was performed in PBS
(pH 7.4). NMR results confirmed that 14% of total ligands on
amph-NPs were exchanged by amine ligands. To introduce
maleimide groups onto the amino-functionalized NPs, amino-
NPs were mixed with a 40-fold molar excess of sulfo-MBS het-
erobifunctional crosslinkers (Life Technologies) at a final NP
concentration of 10 mg mL−1 in PBS (pH 7.4) and placed on a
shaker for 1 hour at 25 °C. NPs were washed in PBS (pH 7.4)
two times to remove excess unbound linkers by centrifugation
at 14 Kg for 10 minutes using Amicon 30 kDa MWCO filters. A
third wash was performed in PBS (pH 7.2). The concentration
of maleimide-functionalized amph-NPs was measured by UV-
vis (Absorbance at 510 nm) using the gold particles’ known
extinction coeﬃcient (9.372 L g−1 cm−1) and applying Beer’s
law. Antibody solution (Anti-Mouse CD8α Clone 53-6.7 or rat
IgG2a K Isotype Control purchased from eBioscience) was con-
centrated to 4 mg mL−1 and mildly reduced by addition of a
25-fold molar excess of dithiothreitol (DTT) in the presence of
10 mM EDTA for 20 minutes at 25 °C. Excess DTT was
removed via centrifugation using 7 kDa MWCO desalting
columns. Mildly reduced whole antibodies (1 mg mL−1) or
VHH-cysteine were immediately coupled with maleimide-func-
tionalized NPs (5 mg mL−1) at a mass ratio of 4 : 1 NP : protein
in PBS (pH 7.2) overnight. Uncoupled free antibodies or VHHs
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were separated from the particles by centrifugation using an
airfuge (Beckman).
Gel electrophoresis analysis of nanoparticle conjugates
The conjugation eﬃciency of antibody-NP products was quan-
tified by SDS PAGE (NuPAGE™ Novex™ 4–12% bis–tris protein
gels purchased from ThermoFisher Scientific). The concen-
tration of airfuge-purified Ab-NPs was determined by UV-vis
(Absorbance at 520 nm). Ab-NPs (15–30 μg) were reduced in
β-mercapoethanol (βME) for 1–2 days to completely strip
ligands from the particles. Supernatant containing 15–30 μg
NPs (15 μL) was mixed with 5 μL of 4× SDS PAGE sample
loading buﬀer and heated at 80 °C for 10 minutes. Denatured
samples were loaded into gel wells and ran for 40 minutes at
100 kV. Gels were stained with Coomassie blue, imaged using
an ImageQuant gel imager and analyzed by ImageJ software.
Primary cell isolation and antibody staining for mass
cytometry
100 μL of blood was collected via the retro-orbital route, or
spleens were collected from C57Bl/6 mice, and splenocytes or
peripheral blood mononuclear cells (PBMCs) were isolated.
Cell pellets were resuspended in staining buﬀer followed by
antibody staining and fixing: cells were incubated with a
selected antibody cocktail (Anti-Mouse CD45 (30-F11)-147Sm;
Anti-Mouse CD3e (145-2C11)-152Sm; Anti-Mouse CD8a (53-
6.7)-168Er; Anti-Mouse CD4 (RM4-5)-172Yb; Anti-Mouse
CD45R/B220(RA36B2)-176Yb; Anti-Mouse CD11b (M1/70)-
148Nd; Anti-Mouse Ly-6G (Gr-1) (RB6-8C5)-174Yb; Anti-Mouse
CD11c (N418)-142Nd; Anti-Mouse F4/80 (BM8)-159Tb; Anti-
Mouse NK1.1 (PK136)-170Er; Anti-Mouse CD64 (X54-5/7.1)-
151Eu; Anti-Mouse CD326 [EpCAM] (G8.8)-165Ho) at 25 °C for
30 minutes, excess antibodies were removed by centrifugation,
and cells were stained with cell-ID™ Intercalator-Ir in fix
and perm solution (detailed protocol available from
Fluidigm website. https://www.fluidigm.com/productsupport/
cytof-helios). Prior to CyTOF analysis, fixed cells were washed
in MaxPar staining buﬀer twice and MaxPar water once to
remove excess iridium. Cells were resuspended at 0.5–1 million
per mL in 1 : 10 calibration beads (EQ™ Four Element
Calibration Beads, Fluidigm) in water and 250 μL samples
were analyzed by a Fluidigm CyTOF2 at a flow rate of 0.045 mL
min−1 or Helios at a flow rate of 0.030 mL min−1.
TEM imaging of CD8+ T cell thin sections
Following amph-NP or antidbody-conjugated NP treatments,
cells were washed 2 times with pH 7.4 PBS to remove unbound
NPs. The cells were fixed in 2.5% glutaraldehyde + 3% parafor-
maldehyde with 5% sucrose in 0.1 M sodium cacodylate buﬀer
(pH 7.4) for 1 h at 4 °C, pelleted, and post-fixed in 1% OsO4 in
veronal-acetate buﬀer. The cell pellet was stained in block over-
night with 0.5% uranyl acetate in veronal-acetate buﬀer
(pH 6.0), then dehydrated and embedded in Embed-812 resin
(Electron Microscopy Sciences). Sections were cut on a
Reichert Ultracut E microtome with a Diatome diamond knife
at a thickness setting of 50 nm. TEM imaging was conducted
with an accelerating voltage of 80 kV using a JEOL 200 CX
Transmission Electron Microscope at the Center of Materials
Science (CMSE) in MIT.
Vaccine studies
Trp1455–463 (TAPDNLGYM), Trp2180–188 (SVYDFFVWL), and
gp10020–39 (AVGALEGPRNQDWLGVPRQL) peptide antigens
linked to a PEG-DSPE amphiphile were prepared as previously
described.35 B16F10 cells (200 000) were injected subcu-
taneously in the flank of C57BL/6J female mice, and trivalent
amph-vaccines (10 μg each amph-antigen; Trp1, Trp2, gp100)
were administered four days after tumor inoculation s.c. at the
tail base along with adjuvant cyclic-di-GMP (Invivogen, 25 μg
per mouse). Mice were boosted with the same dose of vaccines
7 days post priming. TGFβi treatment (5 μg per mouse; deli-
vered soluble or loaded in CD8-targeting VHH-amph-NPs) was
initiated 8 days post tumor inoculation, and dosed every other
day for a total of 8 doses. Intracellular cytokine staining was
performed on 20 days post tumor inoculation to measure
immune responses against tumor antigens.
Intracellular cytokine staining
Blood from immunized mice was collected (100 μL per mouse)
in EDTA-containing tubes, followed by ACK lysis of red blood
cells. Cells were pelleted on a 96-well plate and washed with
PBS once. Trp1, Trp2, or gp100 peptides (10 μg mL−1) were
added to cells in complete RPMI media and incubated for
2 hours in 37 C. Brefeldin A (eBioscience) was added at the rec-
ommended dilution (1 : 1000), and cells were incubated for
another 4 hours at 37 °C, for a total of 6 hours with peptides,
followed by a single PBS wash. Cells were stained with fixable
live/dead aqua (Life Technologies) for 15 minutes at 4 degrees,
then washed once with flow cytometry buﬀer (PBS 1% BSA
5 mM EDTA). Antibodies staining extracellular proteins (CD4,
CD8, etc.) were added at 1 : 100 dilution to the cell pellets and
incubated for 15 minutes at 4 °C, followed by a single wash
with flow cytometry buﬀer. Cells were fixed using BD Cytofix
for 15 minutes at 4 °C, and washed with BD Perm Wash.
Antibodies against IFN-γ and TNF-α were added at a 1 : 75
dilution in BD Perm Wash for 30 minutes at 4 °C, followed by
BD Perm Wash twice. Cells were resuspended in flow cytome-
try buﬀer and analyzed on a BD LSR Fortessa.
Results and discussion
Drug loading in amph-NPs and impact of amph-NP-mediated
delivery on drug uptake in vitro
Prior studies by the Rotello group have demonstrated that
organic layer-capped gold nanoparticles can sequester hydro-
phobic small molecules in their ligand shell; for example, up
to ∼10 small molecules could be loaded into the ligand shell
of zwitterionic gold nanoparticles with a 2.5 nm in core dia-
meter.36 Inspired by these findings, we evaluated the loading
of a poorly water-soluble TGF-β inhibitor (SB525334, hereafter
TGF-βi) into the shell of amph-NPs by co-dissolving drug and
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particles in 20% ethanol, followed by dialysis to remove the
organic solvent and drive the drug into the particle ligand
shells (Fig. 1a). UV-vis spectroscopy of soluble TGF-βi solutions
showed a distinctive absorption peak at 370 nm (Fig. S1†).
Using amph-NPs with a 2.4 ± 0.75 nm core diam. (Fig. S2a and
b†), approximately 15 TGF-βi molecules were loaded per NP, as
detected by UV-vis spectroscopy (Fig. 1b) or HPLC analysis (not
shown). Notably, this drug loading corresponds to an increase
in the solubility of the TGF-βi of at least 10-fold. Despite their
small size, amph-NPs showed a substantial improvement over
our prior studies of liposomes as delivery vehicles for TGF-βi,37
with >10-fold more drug molecules per carrier particle than we
achieved with 100 nm-diam. liposomes.
Although most hydrophobic small molecule drugs are
thought to enter cells by passive diﬀusion, accumulation of
therapeutically functional doses of drugs at intracellular
protein targets can still be limiting, even in vitro.38 We hypo-
thesized that small molecules partitioned in the ligand shell of
amph-NPs could be transported into cytosolic compartments,
as we have previously shown that amph-NPs embed within and
penetrate through cell membranes.28–30,39 To test this hypo-
thesis, we first assessed uptake of amph-NPs in primary
murine CD8+ T cells. Gold particle accumulation in T cells was
detectable within 30 minutes and began to plateau by 3 h as
assessed by ICP-OES (Fig. 1c). Parallel analysis of the uptake of
fluorophore-conjugated amph-NPs in T cells by flow cytometry
showed uniform uptake of particles in the entire T cell popu-
lation by 3 h (Fig. 1d). To test the impact of amph-NP delivery
on uptake of TGF-β inhibitor, CD8+ T cells were incubated with
free TGF-βi or amph-NPs loaded with equivalent amounts of
the drug (NP-TGF-βi) for 4 hours, and the resulting intracellu-
lar TGF-βi concentration was quantified via HPLC analysis of
cell lysates. We observed significantly enhanced TGF-βi
accumulation in CD8+ T cells in vitro when cell-penetrating
amph-NPs were used as a chaperone (Fig. 1e): at 5 µg mL−1 of
added free drug, no TGF-βi was detectable in the cells, while
the inhibitor was readily detected in T cells treated with
NP-TGF-βi. A 10-fold higher concentration of free drug still
Fig. 1 TGF-βi drug loading, quantiﬁcation and cellular uptake in CD8+ T cells in vitro. (a) Schematic illustration of small molecule TGF-βi sequestra-
tion in the amphiphilic ligand shell of amph-NPs. (b) Unloaded amph-NPs or amph-NPs loaded with TGF-βi were treated with β-mercaptoethanol to
disrupt the ligand shell followed by UV-vis absorbance measurements to detect released TGF-βi. (c) Primary CD8+ T cells from C57Bl/6 mice were
incubated with 0.1 mg mL−1 amph-NPs at 37 °C for varying times and then total gold content was assessed by ICP-OES (n = 3 samples/condition).
(d) CD8+ T cells were incubated with 0.1 mg mL−1 BODIPY-labeled amph-NPs at 37 °C for 3 h and then analyzed by ﬂow cytometry, compared to
unmanipulated control T cells. (e) Primary murine CD8+ T cells were incubated in serum-containing medium with NP-TGF-βi or free TGF-βi at the
indicated drug concentrations for 4 h, followed by HPLC analysis of intracellular TGF-βi concentrations. *, p < 0.05; ***p < 0.001 by ANOVA with
Tukey’s post test.
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only reached ∼60% of the levels of intracellular drug accumu-
lated in T cells by the amph-NPs. This result suggested that
the membrane penetration properties of amph-NPs can sub-
stantially increase the uptake and retention of small molecules
intracellularly.
Functionalization of amph-NPs with targeting proteins
Having observed clear benefits to delivery of a small molecule
drug into T cells in vitro, we next considered how to direct
these particles to specific target cells in vivo. While the mem-
brane-penetrating capacity of amph-NPs confers superior cyto-
solic delivery capability, keeping them specific to only target
cells in vivo is a challenge, because lipid membranes are
present on every cell. We hypothesized that by conjugating
amph-NPs to antibodies or antibody fragments – which would
themselves have sizes comparable to or larger than the nano-
particle itself – we could transiently block the particles’ cell-
penetrating behavior, enabling targeted uptake into specific
cells. To test this hypothesis, we conjugated intact anti-CD8
antibodies or camelid-derived single-chain VHH targeting moi-
Fig. 2 Functionalization of amph-NPs with whole antibodies or nanobodies. (a) Schematic of 3-step process for functionalization of amph-NPs
with whole antibodies or VHH nanobodies. (b) SDS-PAGE analysis of anti-CD8 IgG antibody-conjugated amph-NPs (lane 1) and unmodiﬁed amph-
NPs incubated with antibodies (lane 2). Particles were treated with β-mercaptoethanol to release ligand from the particles prior to PAGE. (c)
Quantitative analysis of antibody coupling from SDS-PAGE. (d) SDS-PAGE analysis of anti-CD8 VHH-conjugated amph-NPs (lane 1), unmodiﬁed
amph-NPs incubated with VHH (lane 2), and unmodiﬁed amph-NPs alone (lane 3). Particles were treated with β-mercaptoethanol to release ligand
from the particles prior to PAGE.
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eties to amph-NPs at a molar ratio of approximately 1 protein
per particle. Protein conjugation was achieved by first carrying
out a ligand exchange reaction of 11-amino-undecanethiol
ligands (AUT) with the MUS/OT ligand shell of the particles,
and using 1H NMR to quantify changes in the ligand shell
composition (Fig. 2a, step 1). The ligand ratio was optimized
to achieve a final ligand layer composition of MUS : OT : AUT =
6 : 3 : 1, corresponding to 10% ligand replacement (Fig. S3†).
Next, the introduced amines were modified with a maleimide
functional group using the heterobifunctional linker m-malei-
midobenzoyl-N-hydroxysulfosuccinimide ester (Sulfo-MBS,
Fig. 2a step 2). Finally, maleimide functionalized amph-NPs
were mixed with either dithiothreitol (DTT)-reduced whole
anti-CD8 antibodies or anti-CD8 nanobodies (camelid VHHs32)
bearing a free cysteine to conjugate targeting proteins to the
particles (Fig. 2a step 3). After optimization of reaction con-
ditions, SDS-PAGE analysis showed that ∼1 antibody was con-
jugated per particle, whereas control particles (without male-
imide functionalization) resulted in minimal non-specific
binding (Fig. 2b and c). VHH-conjugated particles were simi-
larly prepared with on average 0.77 proteins per particle; non-
specific binding of VHH proteins to control amph-NPs without
maleimide functional groups was undetectable (Fig. 2d).
We recently demonstrated that the biodistribution of metal-
lic nanomaterials such as gold nanoparticles can be precisely
quantitated in tandem with deep cellular phenotyping using
mass cytometry by time of flight (CyTOF).40 Calibration of the
mass cytometer allows the mean number of nanoparticles per
cell to be directly calculated. To test whether anti-CD8 anti-
body or VHH-conjugated amph-NPs would enhance particle
accumulation in CD8+ T cells, while reducing oﬀ-target uptake
in other cell types, we isolated splenocytes from C57BL/6 mice
and incubated the cells with anti-CD8-NPs or unmodified
control NPs at equivalent gold mass concentrations (10 μg mL−1)
for an hour. Unbound NPs were then removed by washing
and the cells were stained with metal-conjugated phenotyping
antibodies for CyTOF analysis. CD8+ T cells in the splenocyte
culture showed a substantial increase in gold uptake per cell
and an overall more homogenous gold concentration across
the population when incubated with anti-CD8-NPs vs. unfunc-
tionalized nanoparticles (Fig. 3a). By contrast, CD4+ T cells
took up both anti-CD8-NPs and unmodified amph-NPs at
similar low levels (Fig. 3b). We also observed a decreased
intensity of CD8 staining on CD8+ T cells incubated with
anti-CD8-NPs, due to competitive binding of the antibody-con-
jugated nanoparticles with the phenotyping antibody (Fig. 3a).
Quantitatively, anti-CD8 functionalization increased amph-NP
uptake in CD8+ T cells by 9.2-fold in vitro, and reduced oﬀ-
target uptake in most other cell types (Fig. 3c). We carried out
a similar experiment with anti-CD8 VHH-NPs, incubating
unmodified or VHH-conjugated amph-NPs with splenocytes,
and characterized uptake in several lymphocyte populations by
mass cytometry. As shown in Fig. 3d, VHH conjugation also
enhanced uptake of the particles in CD8+ T cells, by 5.3-fold
relative to unmodified amph-NPs. (Note that this experiment
was performed with a 100-fold lower total particle concen-
tration relative to Fig. 3a–c, hence the lower quantitative
amount of particles accumulated in the cells). Thus, uptake
into specific target cells was greatly increased by antibody or
VHH targeting of amph-NPs in vitro.
Fig. 3 Quantiﬁcation of antibody-mediated uptake of amph-NPs in
lymphocytes in vitro. (a–c) Splenocytes from C57Bl/6 mice were incu-
bated with 10 µg mL−1 (gold mass) amph-NPs or anti-CD8-conjugated
amph-NPs for 1 h, then stained with phenotypic antibodies and analyzed
by mass cytometry. Shown are representative cytometry graphs overlay-
ing uptake of amph-NPs (blue) and anti-CD8-NPs (red) in CD8+ (a) and
CD4+ (b) T cells, and quantitative mean nanoparticle uptake per cell
from CyTOF (c, n = 3 samples/condition). (d) Splenocytes were incu-
bated with 0.1 μg mL−1 amph-NPs or VHH-NPs at 37 °C for 1 h then
stained and analyzed by mass cytometry. ****, p < 0.0001;
***, p < 0.001; **, p < 0.01; n.s., not signiﬁcant by ANOVA followed by
Tukey’s post test.
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Intracellular traﬃcking of antibody-functionalized amph-NPs
To investigate the impact of antibody-mediated targeting on the
intracellular traﬃcking of amph-NPs, we visualized nano-
particle distributions within T cells at serial time points after
incubation with the cells by TEM imaging of thin cell sections.
Primary murine splenic CD8+ T cells were cultured in the pres-
ence of unmodified amph-NPs or anti-CD8-NPs for 30 minutes,
after which particles in the supernatants were removed by
washing. TEM imaging revealed pronounced localization of
anti-CD8-NPs at the surface of T cells following 30 minutes of
incubation (Fig. 4a), while free amph-NPs showed little to no
surface-bound NPs, although amph-NPs localized to endo-
somes were observed in some cells (Fig. 4b). We next incubated
T cells with anti-CD8-NPs for 30 min, washed the cells to
remove unbound particles, and incubated the cells for an
additional 4 h or 24 h to allow subsequent cellular internaliz-
ation of surface-bound particles to occur prior to fixing for TEM
imaging. At 4 hours post incubation, most anti-CD8-NPs were
entrapped in endosomes, likely via receptor mediated endocyto-
sis (Fig. 4c). Interestingly, we observed cytosolic dispersion of
anti-CD8-NPs at 24 h post incubation, implying that amph-NPs
can still traverse intracellular membranes despite their initial
chemical conjugation to the antibody (Fig. 4d). We expect that
once bound and internalized by the target cells, the targeting
antibody is proteolyzed in endolysosomes, freeing the amph-NP
to subsequently disperse into the cytosol with its drug cargo.
In vivo targeting of T cells with antibody- and VHH-
functionalized amph-NPs
Notably, unlike most published antibody-conjugated nano-
particles, where the particle is significantly larger than the tar-
geting moiety, amph-NPs (∼3–4 nm outer diameter with
ligand shell) are smaller than an antibody (∼10 nm). We
speculated that this design would result in a more antibody-
like biodistribution and pharmacokinetics, promoting nano-
particle targeting eﬃciency. To test the in vivo targeting
eﬃciency of whole antibody-conjugated particles, anti-CD8-
NPs were injected intravenously via the tail vein followed by
isolation of peripheral blood mononuclear cells 24 hours post
injection for mass cytometry analysis. Anti-CD8 antibody con-
jugation increased amph-NP uptake in CD8+ T cells over the
unmodified particles by 35-fold (Fig. 5a). However, we also
observed increased uptake of antibody-conjugated amph-NPs
in non-CD8+ cells (ranging from 1.3-fold to 6.7-fold higher
than unmodified nanoparticles across diﬀerent cell types),
especially myeloid-derived CD11b+ DCs and CD11b+ F4/80+
macrophages in the blood (Fig. 5a), which we expect may be
due to uptake of the whole antibody-conjugated particles via
Fc receptors expressed by these cell types.
To further improve targeting eﬃciency and reduce uptake
in FcR-expressing phagocytes, we next evaluated the use of
anti-CD8 VHH at the targeting agent. To evaluate their behav-
ior in vivo, 100 μg unmodified amph-NPs or VHH-amph-NPs
were administered intravenously via the tail vein in C57Bl/
6 mice. Strikingly, 24 hours post injection, VHH conjugation
increased uptake of the nanoparticles in blood CD8+ T cells by
40-fold, from 11 particles per cell to 445 particles per cell,
while minimal uptake was observed in other lymphocyte popu-
lations (Fig. 5b). Intriguingly, uptake on myeloid cell popu-
lations was low for both targeted and untargeted nanoparticles
except for a population of CD11b+ CD11chi DCs, where anti-
CD8 VHH conjugation resulted in reduced oﬀ-target uptake
(Fig. 5c). VHH conjugation not only increased the number of
Fig. 4 TEM imaging of antibody-targeted amph-NP uptake by CD8+ T cells. T Cells were incubated with 80 µg mL−1 anti-CD8-conjugated amph-
NPs (a, c, d) or unmodiﬁed amph-NPs (b) for 30 min after which were either ﬁxed immediately (a–b) or incubated in serum-containing media
(without NPs) for another 4 hours (c) or 24 hours (d) to allow for NP internalization and dispersion. Shown are representative TEM images of thin
sections prepared from each time point.
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NPs per CD8+ cell, but also increased the percentage of CD8+ T
cells that contained NPs (Fig. 5d and e). By comparison,
VHH-NP showed lower uptake in other cell types such as CD4+
T cells or neutrophils (Fig. 5d and e). Altogether, these data
suggest VHH-targeting provided substantially enhanced deliv-
ery of amph-NPs to the targeted CD8+ T cell lymphocyte
population.
Targeting of TGF-βi to T cells in vivo
Finally, as a preliminary test of the capacity of amph-NPs to
deliver drugs to lymphocytes in vivo and functionally impact
an immune response, we evaluated the impact of targeting
TGF-βi to CD8 cells in the setting of a cancer vaccine. TGF-β
signaling inhibits the production of the key eﬀector molecules
interferon-γ (IFN-γ), perforin, Granzyme A and B, and Fas
ligand by T cells,9–14 and thus we expected that inhibition of
this pathway during vaccination could increase T cell eﬀector
functions. As a proof of concept, we established a melanoma
murine model, and vaccinated the tumor-bearing mice to
prime antigen-specific CD8+ T cell responses. Four days after
the initial vaccination, mice were repeatedly dosed with
soluble TGF-βi (sol. TGF-βi) or TGF-βi loaded in the ligand
shell of anti-CD8 VHH-conjugated amph-NPs (VHH-NP(TGF-
βi)) (Fig. 6a). Peripheral blood mononuclear cells (PBMCs)
were isolated 16 days after the initial vaccination, restimulated
by peptide antigens in culture for 6 hours, and analyzed via
flow cytometry to detect cytokine-producing antigen-specific
T cells. Vaccination alone elicited a clear T cell response to all
Fig. 5 Antibody- and VHH-mediated targeting of nanoparticles to T cells in vivo. (a) C57Bl/6 mice (n = 3 animals/group) were injected i.v. with
150 µg amph-NPs or anti-CD8-NPs, and particle uptake in PBMCs was analyzed 24 h later by mass cytometry. (b–d) C57Bl/6 mice (n = 3 animals/
group) were injected i.v. with 100 µg amph-NPs or VHH-NPs. Twenty-four hours later particle uptake in leukocytes was analyzed by mass cytometry.
Shown is uptake in peripheral blood lymphocytes (b) and myeloid cells (c), representative mass cytometry plots from several cell populations
showing percentages of NP+ cells (d), and quantitation of the mean NP+ cells (e). ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; n.s. not sig-
niﬁcant by two-way ANOVAwith Tukey’s multiple comparison test.
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3 peptide antigens, with ∼8% of all CD8+ T cells in circulation
exhibiting with a polyfunctional (IFN-γ+TNF-α+) response to
the Trp1 antigen alone (Fig. 6b and c). Adding treatment with
the untargeted free TGF-β inhibitor had no impact on T cell
functionality. By contrast, targeting of the drug to T cells with
VHH-NPs approximately doubled the proportion of cytokine-
producing T cells, increasing production of both IFN-γ and
TNF-α by the responding cells (Fig. 6b and c). In addition to
increasing the number of cytokine-producing T cells, targeted
TGFβi delivery also increased the levels of IFN-γ produced by
each cell (Fig. 6d). Unfortunately, the enhanced T cell func-
tionality elicited by targeted TGF-βi therapy in this aggressive
tumor model led to only a trend toward slightly slowed tumor
growth that was not statistically significant compared to vacci-
nation alone (Fig. S4†); further optimization of treatment regi-
mens for more impactful therapeutic outcomes will be a focus
of future work. Vaccination combined with soluble inhibitor
treatment trended toward a slightly worse outcome than vacci-
nation alone (Fig. S4†). Thus, targeted TGF-βi delivery clearly
enhanced cytokine functionality of T cells over traditional drug
therapy in the setting of therapeutic vaccination.
Conclusions
In conclusion, we demonstrated that small (2–4 nm in dia-
meter) gold nanoparticles with amphiphilic ligand coatings
have the dual properties of absorbing hydrophobic small mole-
cules and an ability to disperse in cells via spontaneous lipid
membrane penetration or following endocytic uptake by non-
disruptively penetrating endosomal membranes. Given these
properties, amph-NPs can transport useful doses of drugs
Fig. 6 TGFβi delivered via VHH-conjugated amph-NPs augments endogenous CD8+ T cell vaccine responses. (a) Timeline of administration of Trp1,
Trp2, and gp100 trivalent vaccines and TGFβi administration to tumor-bearing C57Bl/6 mice (n = 5 animals/group). (b) Representative ﬂow cytometry
plots of intracellular cytokine staining to detect antigen-speciﬁc CD8+ T cell responses from 3 individual mice to each of the 3 peptide antigens in
peripheral blood at day 20. (c) Quantitative analysis of percent of IFN-γ- and TNF-α-expressing cells amount total CD8+ T cells. *, p < 0.05; n.s. not
signiﬁcant by ANOVA followed by Tukey’s post test. (d) Example histograms (upper panels) and mean ﬂuorescence intensities (MFI, lower panels) of
IFN-γ expression in CD8+ T cells after ex vivo antigen restimulation. ***, p < 0.001; **, p < 0.01; *, p < 0.05 by two-tailed unpaired t test.
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across membrane barriers to their cytosolic protein targets to
activate or abrogate the corresponding signaling cascades. As
an example, we showed that TGF-βi encapsulated in the ligand
shell of amph-NPs via hydrophobic–hydrophobic interactions
reached a higher intracellular concentration in CD8+ T cells
in vitro compared to its free soluble form. Targeted inhibition
of TGF-β signaling pathway in circulatory CD8+ T cells in vivo
was achieved by antibody or VHH conjugation, which when
combined with a vaccine significantly enhanced cytokine pro-
duction by antigen-specific CD8+ T cells. These data provided a
proof of principle for utilizing amph-NPs as an eﬀective lym-
phocyte-targeted cytosolic small molecule delivery platform.
The advantage of this delivery platform is two fold: one, due to
the metallic gold core the number of drug carriers per cell can
be precisely tracked in vivo for toxicology studies. Two, the
capability to solubilize high concentrations of hydrophobic
small molecules into amph-NP carrier is superior to conven-
tional lipid or polymer-based approaches. While amph-NPs are
designed to target specific lymphocyte populations, a key ques-
tion is which of these systems is more eﬀective in targeting
cells in the circulation vs. tumors vs. lymphoid organs, and
answering this will be an important component of future work.
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